Non-Disclosure Agreement (NDA) for Pharma

Why Pharma-specific Non-Disclosure matters

In Pharma, the main risk is not simply that someone “shares a secret.” It is that one disclosure can damage a patent position, contaminate a regulatory strategy, interrupt manufacturing, or trigger privacy and pharmacovigilance issues that are expensive to unwind. A preclinical data package may reveal a compound’s mechanism of action, salt form, dose range, or stability profile. A manufacturing discussion may expose process parameters, yield data, impurity profiles, or supplier identities. A diligence deck may include unpublished trial results, endpoint disputes, or CMC issues that would materially affect valuation. If the NDA is loose, the recipient may reuse the information in a competing program, brief a different team internally, or pass it to a CRO, CMO, or investor without proper controls.

Pharma also sits at the intersection of IP and regulation. The same document can be a trade secret, a basis for patent support, and evidence in a regulatory filing. If disclosure is not tightly governed, you can lose practical secrecy protections, create disputes over inventorship or ownership of improvements, or complicate exclusivity and licensing negotiations. In cross-border collaborations, the NDA must also account for privacy law, export controls, and local secrecy rules. That is why a Pharma NDA is really a risk-allocation tool: it defines what may be shared, who may see it, how long it stays protected, and what happens if the recipient needs to disclose to a regulator, auditor, or subcontractor.

Key considerations for Pharma

• Define the protected material by use case, not just by label. In Pharma, “Confidential Information” should clearly include unpublished compounds, assay data, study protocols, pharmacovigilance reports, batch records, source code for device-linked products, and manufacturing know-how, whether oral, written, electronic, or sample-based.
• Control who can receive the information internally and externally. Limit access to employees and contractors with a need to know, and require written confidentiality obligations for CROs, CMOs, consultants, statisticians, and affiliates that are actually involved in the project.
• Address sample handling and reverse engineering expressly. If you are sharing biological samples, reference standards, intermediates, or finished product, the NDA should prohibit chemical analysis, deconstruction, sequencing, and other attempts to discover composition or process details unless the parties clearly agree otherwise.
• Separate evaluation use from development use. A licensing NDA for a target or platform may allow diligence only, while a development alliance may need broader use rights for protocol design, transfer of technical data, and regulatory support. Mixing these up creates scope disputes later.
• Deal with regulated disclosures and mandatory reporting. The recipient may need to disclose information to FDA, EMA, MHRA, a notified body, an IRB/IEC, ethics committee, auditor, or insurer. The NDA should require notice, minimum necessary disclosure, and cooperation on protective treatment where lawful.
• Build in data-protection and clinical-trial controls. If patient data, site data, or investigator information is involved, the NDA should be consistent with GDPR, UK GDPR, HIPAA where applicable, and the underlying data processing agreements.
• Cover supply-chain sensitivity. For API, excipients, packaging, and cold-chain products, suppliers may be able to infer commercial volumes, launch timing, or product specifications from the disclosed information. That often needs an explicit non-use and non-solicitation framework.

Essential clauses

• Confidential Information: Defines the information protected and should capture technical, regulatory, clinical, manufacturing, commercial, and patient-related data that Pharma parties routinely exchange.
• Purpose Limitation: Restricts use of the information to a specific evaluation, research, licensing, or supply purpose so the recipient cannot repurpose it for a competing program.
• Permitted Recipients: Allows disclosure only to named categories such as employees, counsel, auditors, CROs, CMOs, and consultants who are bound by written confidentiality duties.
• Non-Use Covenant: Prevents the recipient from using the information for any purpose outside the stated project, which matters when data could accelerate internal pipeline decisions.
• Non-Disclosure Covenant: Bars sharing the information with third parties except as expressly permitted, including cross-functional teams, affiliates, or outsourcing vendors.
• Sample and Material Restrictions: Prohibits reverse engineering, sequencing, decompilation, chemical analysis, or other attempts to derive composition, process, or structure from provided materials.
• Trade Secret Protection: Recognizes that certain Pharma data may be trade secrets and requires reasonable safeguards, prompt notice of leaks, and return or destruction procedures that preserve secrecy.
• Compelled Disclosure: Requires advance notice, cooperation, and disclosure only to the extent required by law, subpoena, regulator request, or court order.
• Residuals / Memory Clause: Should usually be narrowed or excluded in Pharma, because broad “residual knowledge” language can undermine protection of scientific know-how and platform data.
• Ownership of Improvements: Clarifies whether any inventions, modifications, feedback, or derivative work generated during discussions belong to one party, jointly, or to the creating party.

For many Pharma deals, the most negotiated points are the purpose limitation, permitted recipients, sample restrictions, and compelled disclosure language. If you need to build and compare clause options quickly, LexDraft’s templates can help you start from a Pharma-friendly baseline and adapt the drafting in Word without rebuilding the NDA from scratch.

Industry-specific regulatory considerations

Pharma NDAs often sit alongside regulations rather than replacing them. If patient or subject information is involved, the agreement should be consistent with privacy laws such as the EU GDPR and UK GDPR, and with local health-data rules where relevant. In the United States, HIPAA may apply to protected health information if a covered entity or business associate is involved, and a separate Business Associate Agreement may be required. For clinical collaborations, the NDA should not conflict with IRB or IEC obligations, Good Clinical Practice principles under ICH E6, or sponsor obligations to monitor and report safety signals.

On the product side, FDA, EMA, and MHRA interactions often require disclosure of otherwise confidential information. The NDA should therefore allow limited disclosure for regulatory submissions, inspections, audits, and pharmacovigilance, while still requiring notice and protective handling where possible. Manufacturing and quality information may also implicate GMP expectations under applicable FDA cGMP rules and EU GMP standards. If materials or data cross borders, export controls, sanctions, and customs restrictions may apply, especially for biologics, dual-use research, or sensitive technologies. Trade secret law is also relevant: in the US, the Defend Trade Secrets Act and state trade secret laws generally reward reasonable secrecy measures, so a weak NDA can make enforcement harder. In Europe, the EU Trade Secrets Directive framework similarly depends on protecting information with reasonable steps. For medical devices or combination products, ISO 13485 and related quality agreements may intersect with the NDA, especially when technical files or supplier audits are shared.

Best practices

• Use a project-specific definition of “Purpose.” “Evaluating a possible license to the XYZ antibody program” is better than “business discussions,” because it narrows what the recipient can do with your data.
• Require written approval before sharing with affiliates or subcontractors. In Pharma, a recipient’s affiliate or CRO may be in another jurisdiction with different privacy and secrecy rules.
• Include a clean sample protocol. State whether materials may be used only for testing, whether leftovers must be returned, and whether any testing data must be deleted or anonymized.
• Attach a disclosure matrix for clinical or regulatory deals. Identify what can be shared with regulators, ethics committees, investigators, labs, investors, and insurers, and who must approve each disclosure.
• Limit retention periods realistically. Some technical and quality records need to be retained for GMP, audit, or litigation hold purposes; do not require destruction that would violate recordkeeping obligations.
• Address publication rights in academic collaborations. If a university, investigator, or medical center is involved, the NDA should allow manuscript review and delay publication long enough to file patents.
• Make IP ownership explicit. If parties may generate inventions, assays, formulations, or device integrations, the NDA should not leave ownership to implication.
• Draft for enforceability across borders. Use a governing law and forum clause that matches where assets, witnesses, and injunctions are likely to matter, and make sure the confidentiality obligations work in the countries where the work will actually happen.

Common pitfalls

One common mistake is using a generic NDA for a licensing discussion and forgetting that the recipient will see sample data, CMC details, and regulatory strategy. I have seen agreements that protected only “business plans,” which is far too narrow for a compound disclosure package. Another mistake is allowing unrestricted affiliates access. In Pharma, that can mean a parent company, a sister lab, or a foreign development team gets the information with no need-to-know limit.

A second trap is broad residuals language. If the other side can rely on “unaided memory” after the deal ends, it can be hard to prove misuse of scientific know-how or platform-specific methods. A third trap is failing to address samples. If you send a formulation sample or cell line without a clear no-reverse-engineering clause, the recipient may argue the NDA did not prohibit analytical testing.

Finally, people often forget mandatory disclosure workflows. For example, a CRO may need to share safety information with a regulator or ethics committee, or a bidder in a partnership process may need to show materials to an outside patent lawyer. Without notice and minimum-necessary language, those disclosures can become disputes very quickly.

How to draft one in Word with LexDraft

Start with the right Pharma NDA template inside Word, rather than editing a generic NDA line by line. With LexDraft, you can open the add-in, pick a drafting template, and tailor the key variables: party names, purpose, sample restrictions, permitted recipients, and governing law. Next, insert Pharma-specific clauses for clinical data, regulatory disclosure, and trade secret protection directly in the document, so your edits stay in one place.

Then review the fallback positions: residuals, compelled disclosure, retention, and ownership of improvements. Finally, use the Word workflow to redline, compare versions, and produce a clean draft for the business team or external counsel. If you need a faster starting point or want to compare options, the features and pricing pages show how LexDraft fits different drafting volumes, including the free tier and paid plans.

Frequently asked questions